Excelsior Biopharma (6496) — Cash Flow Reinvestment Rate
Excelsior Biopharma (6496) has a Cash Flow Reinvestment Rate of 6.86x as of June 2025, reinvesting NT$26.07 Million (capex NT$14.44 Million plus investments NT$-11.63 Million) from operating cash flow of NT$3.80 Million. See Excelsior Biopharma (6496) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Excelsior Biopharma Cash Flow Reinvestment Rate (2017–2022)
Historical reinvestment intensity for Excelsior Biopharma across 5 annual periods. For the full cash flow conversion analysis, see how efficiently does Excelsior Biopharma generate cash.
Annual Cash Flow Reinvestment Rate for Excelsior Biopharma (2017–2022)
Year-by-year capital reinvestment analysis for Excelsior Biopharma. See 6496 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 37.88x | NT$207.78 Million | NT$5.49 Million | NT$7.78 Million | ▲ +23704.4% |
| 2021 | 0.16x | NT$8.88 Million | NT$55.82 Million | NT$2.88 Million | ▲ +89.2% |
| 2020 | 0.08x | NT$43.80 Million | NT$520.81 Million | NT$11.62 Million | ▼ -74.3% |
| 2018 | 0.33x | NT$41.51 Million | NT$126.92 Million | NT$9.54 Million | ▲ +524.0% |
| 2017 | 0.05x | NT$18.32 Million | NT$349.47 Million | NT$18.10 Million | — |